Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy

Vista sencilla de ítem
dc.contributor.authorBarrón-Barrón, Feliciano
dc.contributor.authorSánchez, Roberto P.
dc.contributor.authorArroyo-Hernández, Marisol
dc.contributor.authorBlanco, Carolina
dc.contributor.authorZatarain-Barrón, Zyanya Lucia
dc.contributor.authorCatalán, Rodrigo
dc.contributor.authorRamos-Ramírez, Maritza
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorFlores-Estrada, Diana
dc.contributor.authorArrieta, Oscar
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.date.accessioned2020-11-12T21:40:33Z
dc.date.available2020-11-12T21:40:33Z
dc.description.abstractenglishIntroduction:Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially lifethreatening immune-related adverse event (irAE), especially in non-small cell lung cancer(NSCLC) patients. Currently, the potential for increased irAE in patients who receiveradiotherapy is scarcely known, although a connection between antitumor immuneresponses and irAEs has been suggested. In this study, we evaluated the developmentof ICIP in non-small cell lung cancer patients with prior radiotherapy, treated withimmunotherapy in the second-line.Methods:In this retrospective trial, we included patients treated with second-lineimmunotherapy at the National Cancer Institute in Mexico City from February 2015 toFebruary 2018. Clinical, radiological and treatment variables were evaluated accordingto the presence of ICIP as defined by the Common Terminology Criteria for AdverseEvents (4.0) in patients with or without a previous (≥months) history of radiotherapy.Results:Among 101 NSCLC patients who received treatment with ICIs, 22 patients(21.8%) were diagnosed with ICIP, of which 73% (16/22) had a history of radiotherapy(OR 6.04, 95% CI 2.03−18.0,p<0.001). Median progression free survival and overallsurvival were similar in patients who developed ICIP compared with those who did not,however, patients who presented grade≥2 ICIP had an increased risk of mortality (HR2.54, 95% CI 1.20−5.34,p= 0.014).Conclusion:In this real-world cohort of NSCLC patients treated with ICI, the historyof prior radiotherapy was associated with increased risk for ICIP development. Unlikeother irAEs, grade≥2 ICIP is an independent prognostic factor for decreased survivalin NSCLC patients.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.3389/fonc.2020.570233
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn2234-943X
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/5058
dc.language.isoeng
dc.publisherFrontiers Media S.A.spa
dc.publisher.journalFrontiers in oncologyspa
dc.relation.ispartofseriesFrontiers in oncology, 2234-943X, Vol. 10, Nro. 29, 2020spa
dc.relation.urihttps://www.frontiersin.org/articles/10.3389/fonc.2020.570233/full
dc.rightsAttribution 4.0 International*
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2020-09-29
dc.rights.localAcceso abiertospa
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.keywordsCheckpoint immune therapyspa
dc.subject.keywordsPneumonitisspa
dc.subject.keywordsRadiotherapyspa
dc.subject.keywordsNSCLCspa
dc.subject.keywordsLung cancerspa
dc.subject.keywordsImmune related adverse effectsspa
dc.titleRisk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapyspa
dc.title.translatedRisk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapyspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Feliciano Barrón, Roberto Sánchez_2020.pdf
Tamaño:
713.44 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos